The CounterAct solution provides Human Safe commercial UV disinfection which significantly reduces surface and airbourne pathogens and viruses in indoor spaces. This product uses the only far-UVC virucidal and germicidal UVC technology with a patented filter that prevents longer UVC wavelengths from being emitted.
We are currently seeking applications from venues to join a pilot program using Christie's CounterAct Fixtures. Apply below:
Watch the replay of the live discussion on 3rd February 2021 with industry leaders debating the potential of far UVC-light in the fight against COVID-19
Find out moreCoronavirus is airborne. So how do we clean the air that we breathe? As museums, theme parks and other attractions reopen in a post-Covid world, new far-UVC technology will help operators ensure their sites are as safe as possible.
Find out moreRead the datasheet for the Far UVC light solution Christie® CounterAct™ with Care222
Find out moreExploratory clinical trial on the safety and bactericidal effect of 222-nm ultraviolet C irradiation in healthy humans
Find out moreA report on research carried out by Vagelos College of Physicians and Surgeons at Columbia University Irving Medical Center which shows that Far UVC light kills Covid.
Find out moreThe Human2dotzero CounterAct pilot program is designed to establish a number of industry beacons, demonstrating best use of the technology and integrated alongside other COVID-secure measures, the program offers deep and extensive technical support, marketing support and preferential pricing. Please enter your details with a description of your venue and a short description of the other COVID-secure methods that you have or plan to implement.